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Abstract
The trillions of bacteria that naturally reside in the human gut collectively constitute the complex 
system known the gut microbiome, a vital player for the host’s homeostasis and health. However, 
there is mounting evidence that dysbiosis, a state of pathological imbalance in the gut microbiome 
is present in many disease states. In this review, we present recent insights concerning the gut 
microbiome’s contribution to the development of colorectal adenomas and the subsequent 
progression to colorectal cancer (CRC). In the United States alone, CRC is the second leading 
cause of cancer deaths. As a result, there is a high interest in identifying risk factors for adenomas, 
which are intermediate precursors to CRC. Recent research on CRC and the microbiome suggest 
that modulation of the gut bacterial composition and structure may be useful in preventing 
adenomas and CRC. We highlight the known risk factors for colorectal adenomas and the 
potential mechanisms by which microbial dysbiosis may contribute to the etiology of CRC. We 
also underscore novel findings from recent studies on the gut microbiota and colorectal adenomas 
along with current knowledge gaps. Understanding the microbiome may provide promising new 
directions towards novel diagnostic tools, biomarkers, and therapeutic interventions for CRC.
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Introduction
Globally in 2012 alone, colorectal cancer (CRC) accounted for approximately 694,000 
deaths (approx. 8.5% of total cancer deaths) and 1.36 million new cases [1]. In the United 
States, CRC is the third most commonly diagnosed cancer and the second leading cause of 
cancer deaths and will account for about 136,830 new cases and 50,310 deaths in 2014 [2]. 
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The annual economic burden of CRC in 2010 was approx. 14.1 billion dollars and this is 
expected to increase to about 17.4 billion dollars in 2020 [3]. Mortality from CRC is more 
broadly associated with metastatic disease; therefore, early detection and screening are vital.
CRC occurs in a stepwise fashion beginning with abnormal cell proliferation, and aberrant 
crypt foci leading to the development of adenomatous polyps, which are widely considered 
to be CRC precursors [4]. Colonic polyps are mostly classified on the basis of their 
properties to progress to malignancy (hyperplastic or adenomatous) as well as their structure 
including types (sessile, pedunculated, and flat), shape (tubular, villous, serrated) and size 
(small 1–5 mm, medium 5–10 mm, and large ≥ 10mm) [5]. Hyperplastic polyps are usually 
small, located in the rectum and sigmoid colon, and are generally thought to have no 
malignant potential. However, subsets of serrated hyperplastic polyps are associated with a 
risk of CRC [6]. Adenomatous polyps or adenomas account for approximately 70% of colon 
polyps and have the potential to progress to CRC over time if not screened and removed by 
colonoscopy or sigmoidoscopy [7].
In clinical settings, the number, and structure (shape, size, and type) of adenomatous polyps 
are vital indicators when predicting which patients are more prone to develop CRC based on 
polyp morphology. Thus, adenomas are important intermediates in colorectal carcinogenesis 
and identifying adenoma risk factors is important in preventing CRC. Although the specific 
etiologic agents responsible for adenomas and CRC are unknown, several genetic and 
environmental risk factors have been implicated.
Risk factors for colorectal adenomas and CRC
The role of genetic alterations in the progression of adenomas to CRC was initially 
described by Fearon and Vogelstein [2]. Genetic mutations in oncogenes (KRAS), tumor 
suppressor genes such as adenomatous polyposis coli (APC), CTNNB1 and p53, [2, 8–13], 
and alterations in pathways that revolve around chromosomal and microsatellite instability 
(MSI), mismatch repair (MMR) [14, 15], and CpG island methylation (CIMP) [16, 17] are 
key players in colorectal adenomas and CRC [18].
In addition, findings from genome-wide association studies (GWAS) support a polygenic 
model of CRC in which several common low penetrance susceptibility genes such genetic 
variants in vitamin D [19], cyclin D1, and Smad7 [20] contribute to increased risk of 
adenoma and CRC [21, 22]. Family history and age are also considered to be important CRC 
predictors as they have been associated with higher risk of adenomas and CRC. Studies 
suggest that genetic predisposition and somatic alterations in combination with 
environmental factors are responsible for CRC as a complex disease [20].
The most common environmental factors implicated in association with colorectal adenomas 
and CRC are lifestyle and diet. Several studies demonstrate that unhealthy diets such as 
those high in fat, alcohol, red meat, and low in fiber are associated with increased risk of 
adenomas and CRC [23]. Moreover, smoking, obesity, low physical activity [24, 25], sex 
(increased risk for males), ethnicity (predominantly in Non-Hispanic Black population [19, 
26], and lifestyle (lack of physical exercise) all contribute to the development of CRC. 
Adopting a healthy lifestyle, incorporating regular exercise and a diet high in fruits, 
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vegetables, and high-fiber foods could potentially reduce the risk of CRC. However, not all 
the results from dietary studies are consistent. A pooled study of fiber and CRC reported 
inconsistent findings in which about half of the studies showed a protective effect of fiber 
while the others did not [27]. These discrepancies could relate to the influence of the gut 
microbiota on fiber. The gut microbiota was not assessed in these studies.
Gut microbiota
The human colon hosts a very diverse and complex microbial community comprising an 
estimated 100 trillion bacteria of more than 1,000 heterogeneous species (harboring approx. 
4 million genes) along with viruses, archaea, and fungi. The collective bacterial genome 
referred to as the gut microbiome, harbors 150-fold more genes than the human genome [28, 
29]. Bacterial cells of the gut exceed the total number of host cells in the human body by 10-
fold [30]. These bacteria play key roles in modulating host metabolism such as absorption of 
indigestible carbohydrates, production of vitamins B and K, and promotion, maturation and 
development of innate and cell-mediated immunity and also help to maintain intestinal 
barrier function and appropriate immune response against pathogens [31, 32]. Under normal 
physiological conditions, the gut bacteria and the host co-exist in a state of homeostasis. 
However, the gut microbiota is increasingly associated with a variety of diseases including 
obesity, inflammatory bowel diseases, adenomas, and CRC [12, 33, 34].
Gut microbiota, adenomas, and CRC
Several studies implicate microbial dysbiosis, a pathological imbalance in the microbial 
community, in the etiology of colorectal adenomas and CRC. This is summarized in Fig. 
1A. Shen et al. used molecular fingerprinting and clone sequencing methods to characterize 
the adherent bacterial composition in normal rectal mucosal biopsies and observed that the 
gut bacterial composition of subjects with adenomas differed significantly from that of 
control subjects without adenomas [35]. They reported a higher proportion of 
Proteobacteria and lower abundance of Bacteroidetes in cases than in controls. These initial 
findings were confirmed in a follow-up study that used 16S rRNA gene amplicon 454 
pyrosequencing methods to characterize the gut bacteria. Sanapareddy et al. [36] found an 
overabundance of potential pathogens, Pseudomonas, Helicobacter, Acinetobacter and other 
genera belonging to the phylum Proteobacteria in rectal mucosal biopsies of adenoma cases 
compared to non-adenoma controls [36]. Brim et al. compared the fecal microbiota from a 
small sample group of African American patients with or without colorectal adenomas and 
noted a trend of altered microbial changes between adenoma patients and healthy controls 
[37]. In experimental models of CRC, Wei et al. observed dysbiosis associated with an 
increased abundance of Ruminococcus obeum, and Allobaculum spp. in precancerous lesions 
[38]. These findings suggest that changes in the gut adherent microbial community 
composition may play a role in the development of adenomas.
Other studies have also examined the microbiota in relation to CRC (Table 1). Marchesi et 
al. assessed the microbiota in colon tumors and matching normal tissue and observed 
bacterial dysbiosis in the tumors [39]. In particular, they noted an overabundance of 
Fusobacterium in tumors compared to matching normal tissue. Their initial findings for 
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Fusobacterium and CRC have been confirmed by others [40–45]. Furthermore, some studies 
characterized the microbiota in fecal samples from CRC subjects and healthy controls. 
Sobhani et al. examined fecal samples from CRC patients and controls and found that 
bacterial dysbiosis was associated with CRC and was characterized by an increased 
abundance of Prevotella [46]. Bacterial dysbiosis associated with CRC has been reported to 
have relative decreased abundance of obligate anaerobes, increased potential pathogenic 
bacteria, and reduction in proportions of beneficial butyrate-producing bacteria [45, 47–49]. 
Zackular et al. demonstrated that changes in the gut microbiota associated with 
inflammation and tumorigenesis directly contribute to colorectal cancer [50]. In 
experimental models, they transferred the fecal microbiota of tumor bearing mice to germ 
free mice and showed that the microbiota from the tumor bearing mice (donor) promoted 
tumorigenesis in recipient animals with twice as many colon tumors than mice given healthy 
microbiota. Similar to the donor microbiota, the microbiota of recipient mice was 
characterized by elevated abundance of Akkermansia, Odoribacter, and Bacteroides. Their 
observations suggest that the gut microbiota may be amenable to manipulation with 
antibiotics or probiotics to prevent the development of adenomas and CRC.
The overall consensus from these studies is that a combination of the expansion of 
procarcinogenic bacteria concomitant with the reduction of tolerogenic commensals such as 
Faecalibacterium prausnitzii [51] or spore-forming Clostridium clusters IV and XIV [52] 
may link bacterial dysbiosis to the risk of adenomas and CRC. However, it is difficult to 
discern from human studies whether gut bacterial dysbiosis is a cause or consequence of 
adenomas and CRC.
Specific gut bacteria, adenoma, and CRC
Overall, the mechanisms by which the gut microbiota influences adenoma and CRC 
development remain to be fully established. Moreover, the contribution of specific bacterial 
signatures and potential mechanisms are not yet elucidated. Potential mechanisms include 
promotion of chronic inflammation, DNA damage, and production of bioactive carcinogenic 
metabolites. We describe current reports on some specific bacteria.
Fusobacterium nucleatum: Various studies suggest that overabundance of Fusobacterium 
spp. is a common feature of CRC that may contribute to disease progression from adenoma 
to cancer. However, it is not clear whether Fusobacterium spp. is a cause or consequence of 
adenomas and CRC [53]. Two recent experimental studies provide further mechanistic 
insights into the relationship between F. nucleatum and colorectal neoplasia. Rubinstein et 
al. [54] observed that binding of F. nucleatum via its FadA adhesion molecule to E-cadherin 
leads to activation of β-catenin signaling to induce pro-oncogenic and inflammatory 
pathways (Fig. 1B. I). The second study by Kostic et al. showed that Fusobacterium 
modulates the tumor immune microenvironment to promote inflammation and tumorigenesis 
[43]. In the APC min mouse model of CRC, they showed that Fusobacterium increases 
infiltration of myeloid cells such as CD11b positive T cells, macrophages, and dendritic 
cells to induce an NF-κB-driven pro-inflammatory response to promote CRC. In a 
companion human study, increased FadA expression (> 10–100 times) correlated with 
elevated expression of oncogenic and inflammatory genes in CRC subjects. While these 
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findings support a role for Fusobacterium spp. and FadA in colorectal carcinogenesis, it is 
too early to determine their potential as a CRC biomarker or their utility as potential 
diagnostic and therapeutic targets. Thus, additional studies are needed.
Streptococcus gallolyticus (formerly S. bovis): DNA from S. gallolyticus is present in about 
20–50% of colon tumors compared to less than 5% in the normal colon [55]. It has also been 
associated with increased colonization of collagen-rich surfaces of colorectal adenomas and 
tumors [56]. It is thought that S. gallolyticus may contribute to neoplastic transformation in 
the colon via invasion through a breach in the epithelial barrier or virulence factors, which 
ultimately enhance inflammation and tumorigenesis [55, 56].
Enterotoxigenic Bacteroides fragilis (ETBF): Other bacteria possessing virulence traits such 
as ETBF are pro-oncogenic and may remodel the microbiota as a whole to promote mucosal 
immune responses and epithelial changes, which promote colorectal adenomas and cancer. 
ETBF produces a toxin known as fragilysin (B. fragilis toxin; BFT) which activates the 
Wnt/β-catenin signaling pathway to increase cell proliferation [57]. BFT also activates NF-
kB to induce production of inflammatory mediators. This leads to mucosal inflammation 
and, ultimately, colorectal carcinogenesis [58, 59]. ETBF was shown to promote 
tumorigenesis in a study by Wu et al. in which they colonized the APC min model of 
intestinal neoplasia with a pig isolate of ETBF. They observed a marked increase in colon 
adenoma and tumor formation in mice colonized with ETBF compared to control mice [60]. 
The enhanced tumorigenesis by ETBF could occur via activation of Stat3, induction of 
IL-17 [61] and DNA damage [62]. These observations support a link between bacterial 
antigens, virulence factors and colon adenomas and CRC.
Enterococcus faecalis: In experimental models, certain strains of E. faecalis have been 
associated with CRC and colitis- associated CRC. Some strains promote release of 
extracellular superoxide in host cells. The superoxide is converted by hydrogen peroxide 
could induce DNA damage [63], chromosome instability [64], and cancer in germfree 
Interleukin-10 (IL-10−/−) mice (Fig. 1B. III) [65, 66].
Escherichia coli: DNA damage induced by genotoxic E. coli strains could result in CRC-
initiating lesions. E. coli possessing the polyketide synthase (pks) Genotoxic Island, which 
encodes the enzymatic machinery to make Colibactin may also promote CRC via induction 
of DNA double strand breaks (Fig. 1B. I) [67]. Arthur et al. recently showed that deletion of 
pks from a strain of E. coli results in reduced DNA damage, tumor numbers, and tumor 
invasion, but not inflammation in mono-associated IL10−/− mice treated with azoxymethane 
(AOM) [68]. A few human studies suggest that E. coli harboring the pks is more common in 
CRC and inflammatory bowel disease patients [68, 69]. Thus, these findings lend strong 
support to the contribution of genotoxic E. coli in colorectal cancer.
Acidovorax: Acidovorax spp., an acid degrading member of the phylum Proteobacteria is 
also associated with increased risk of adenomas [36]. Acidovorax may promote colon 
neoplasia through increased metabolism of nitro-aromatic compounds [70] in the gut as well 
as induction of local inflammation by its flagellar proteins [71, 72].
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In addition to DNA damage and superoxide release, activation of inflammation is a common 
theme across these studies. Further research is needed to identify additional mechanisms by 
which bacteria and their virulence factors promote colorectal carcinogenesis. While 
monoassociation studies involving individual bacteria provide useful mechanistic insights, 
they may not fully represent the complex interactions between gut bacterial communities 
and adenomas and CRC.
Bacteria metabolites, adenomas, and CRC
The colonic microbiota influences a wide range of metabolic processes and functions that 
may lead to beneficial or detrimental effects within the human colon. Metabolites produced 
by colonic microbiota might play a critical role in the progression of adenomas to CRC, 
though limited information about the function of most of the gut bacteria and their 
metabolites is known to date. Certain gut bacteria produce short chain fatty acids (SCFAs) 
such as butyrate, which can serve as an energy source for colonic epithelial cells. Wang and 
colleagues observed a reduction in butyrate-producing bacteria in feces of CRC patients 
suggesting that microbial metabolites may contribute to the etiology of CRC [73]. A few 
members of the Clostridium cluster IX, XI, and XVIa are capable of metabolizing primary 
bile acids into secondary bile acids [74]. Secondary bile acids such as deoxycholic acid 
(DCA) might contribute to CRC progression (Fig. 1B. IV) by interacting with host 
metabolism and immunity [75–78].
Few human studies have evaluated the metabolome and microbiota in relation to adenomas 
or CRC. Findings from a recent study suggests that there is a correlation between bacterial 
dysbiosis, the metabolome, and colorectal adenomas [79]. More studies are needed to fully 
explore the relationship between the microbiota, metabolome, adenomas, and CRC.
Summary and conclusions
Although gut bacterial dysbiosis is increasingly recognized as a phenomenon in colorectal 
carcinogenesis, host-bacterial interactions still remain to be fully elucidated. In studying the 
gut microbiota and adenomas or CRC, it is unclear whether sampling the mucosa or the 
luminal content is the most appropriate. Bacteria in the lumen are transient and may be more 
influenced by diet while the adherent mucosal bacteria are considered residents and may be 
more relevant to CRC because of their close contact with the host mucosa and immune cells. 
To date, there is no clear consensus. Studies suggest that bacteria communities in the feces 
differ from the mucosa [80, 81]. Findings from two studies that compared the microbiota in 
mucosa, rectal swabs, and feces of the same patients were inconclusive [82, 83]. Additional 
studies are needed to further define the best sampling location so as to enhance uniformity 
and reproducibility among studies.
The role of the gut microbiota in the progression from adenomas to CRC is undoubtedly 
multifactorial and can affect the various stages of the neoplastic process. Microbial 
dysbiosis, induction of mucosal inflammation, and production of reactive metabolites are all 
processes that might act in concert to set the colonic mucosa on the initial stage of the 
adenoma-carcinoma process. Further research in experimental animal models is necessary to 
better understand the mechanisms that underlay the association between the gut 
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microorganisms and CRC. The intestinal microbiota represents an enormous reservoir for 
the discovery of novel signatures that could be potentially useful as biomarkers and 
predictors for adenomas and CRC. Manipulation of the gut microbiota to restore normal 
physiologic balance might be beneficial in preventing colon adenomas and CRC. 
Furthermore, beneficial or “friendly” bacteria that have been specifically engineered to 
provide desired inflammatory responses and epigenetic expression could have the potential 
to be useful therapeutically in CRC.
In conclusion, the advances in microbiome research provides an opportunity to elucidate the 
exact connections between the host gut microbiome and the onset of CRC, which will 
hopefully lead to safer and more efficacious treatments in the near future.
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A. Schematic diagram of colonic microbiota and adenomas progression to CRC.
Shifts in the balance of host-microbial symbiotic relationships derail the state of homeostasis 
(normal physiology) in the human gut. Dysbiosis, an imbalance of microbial population 
dynamics, is characterized by decreased beneficial commensals/symbionts, overexpression 
of pathogenic microbiota such as genotoxic bacteria, invasive and inflammation triggering 
microbiota, procarcinogenic bacteria and cancer enhancing bacterial antigens and 
metabolites. Consequences of the microbial dysbiosis lead to the chronic inflammation after 
damaging the host defenses (natural barrier) can further drive to the enhancement of small 
adenomas to adenocarcinoma by multistep processes.
B. Proposed mechanisms of specific bacteria and CRC.
The human gut microbiome drives CRC via several mechanisms. Some of the reported 
mechanisms of specific bacteria for the development of CRC are highlighted here.
A. E. coli, Gram-negative facultative anaerobic bacterium, considered as one of the 
potential etiological agents of CRC due to its genotoxins such as Colibactin, and 
cytolethal distending toxin (CDT). These products could induce DNA damage and 
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influence the progression of CRC due to genomic instability from MSI, MMR, and 
mutations.
B. F. nucleatum, Gram-negative anaerobic bacterium, has been linked to CRC 
progression but the exact underlying mechanisms are still unknown. A potential F. 
nucleatum-driven CRC mechanism is its invasion into epithelial cells and 
activation of oncogenic and inflammatory responses through its unique FadA 
adhesin. Active FadA binds to E-cadherin, mediating Fusobacterium attachment 
and invasion into the epithelial cells. This activates β-catenin signaling, leading to 
increased activation of inflammatory genes (NF-κB) and secretion of cytokines 
interleukin-6 (IL-6), IL-8, and IL-18, and oncogenes and drives to adenoma to 
adenocarcinoma.
C. E. faecalis, has been shown to produce extracellular superoxide and hydrogen 
peroxide, which damage DNA and also further enhances chromosomal instability 
in colonic epithelial cells. Chromosomal instability, a common cause of genomic 
instability in tumors, is characterized by nucleotide additions or deletions, 
inversions, translocations, and complex rearrangements, and ultimately contributes 
to the dramatic and unstable alteration in genomic state critical for tumor initiation 
in the colorectum.
D. Gram-positive, spore forming bacteria in cluster IX of the genus Clostridium spp. 
convert primary bile acids into a secondary bile acid such as deoxycholic acid 
(DCA). DCA is widely considered as a carcinogen that is associated with DNA 
damage via the production of free radicals or reactive oxygen species (ROS) and 
implicated to adenoma-inflammation-CRC through enhancing genomic instability 
and inflammation.
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Table 1
Human studies of gut bacteria and colorectal cancer
Study Sampling site Disease Findings Reference
Geng et al. 2013 Tumor/matching normal tissue of 
Chinese CRC patients
CRC Overabundance of Fusobacterium spp., 
Roseburia in tumor tissues and over-
representation of Microbacterium, 
Anoxybacillus bacteria away from tumor 
site
[45]
McCoy et al. 2013 Rectal mucosa Adenoma Fusobacterium spp., higher abundance in 
adenoma subjects.
[43]
Castellarin et al. 
2012
Tumor/matching normal tissue CRC Overabundance of Fusobacterium 
nucleatum sequences
[41]
Chen et al. 2012 Intestinal lumen, mucosa (rectal 
swabs), fecal samples, tumor/
matching normal tissue
CRC Lower bacterial diversity in tumor, altered 
microbial structures in CRC lumen 
compared to mucosa.
CRC might be due to cometabolism by 
lumen microflora and direct interaction 
between host and mucosa-associated 
microbiota.
[81]
Kostic et al. 2012 Tumor/matching normal tissue CRC Altered microbiota, high abundance of 
Fusobacterium sequences and low 
Bacteroides and Firmicutes sequences in 
tumors
[42]
Sanapareddy et al. 
2012
Rectal mucosa Adenoma Bacterial dysbiosis, altered diversity and 
increased richness
[37]
Marchesi et al. 2011 Tumor/matching normal tissue CRC Bacterial dysbiosis, high abundance of 
Fusobacterium in tumors
[40]
Shen et al. 2010 Colonic mucosa of adenoma/non- 
adenoma
Adenoma Bacterial dysbiosis, altered diversity, higher 
abundance of Proteobacteria and lower 
abundance of Bacteroides in adenoma cases
[36]
Ahn et al. 2013 Fecal sample CRC Reduced bacterial diversity in CRC cases [83]
Brim et al. 2013 Fecal sample Adenoma Microbiota changes at the sub-genus level 
but not genome/functions level in colon 
polyps.
[38]
Ohigashi et al. 2013 Fecal samples from CRC/adenoma/
non-adenoma
CRC& Adenoma Significant differences in the intestinal 
environment; altered microbiota (decreased 
particularly obligate anaerobes), decreased 
SCFAs, and elevated pH in CRC.
[48]
Ohigashi et al. 2013 Fecal sample before/after surgery CRC Marked decreased of obligate anaerobes, 
increased pathogenic bacteria, and 
reduction of short chain fatty acids detected 
after surgery for CRC
[49]
Weir et al. 2013 Fecal sample CRC Decrease butyrate producing bacteria [50]
Wu et al. 2013 Fecal sample CRC Bacterial dysbiosis, altered diversity, 
enriched Bacteroides, more abundant of 
Fusobacteriumand Campylobacter sps. 
Decreased butyrate producing bacteria
[46]
Sobhani et al. 2011 Fecal sample CRC Bacterial dysbiosis linked with elevated 
IL-17 in CRC patients
[47]
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